Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03EDQ
|
|||
| Former ID |
DNAP001262
|
|||
| Drug Name |
Vismodegib
|
|||
| Synonyms |
879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Basal cell carcinoma [ICD-11: 2C32; ICD-10: C44; ICD-9: 173] | Approved | [1], [2] | |
| Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00.11; ICD-10: C69-C72, C71] | Phase 2 | [3] | ||
| Company |
Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H14Cl2N2O3S
|
|||
| Canonical SMILES |
CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
|
|||
| InChI |
1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
|
|||
| InChIKey |
BPQMGSKTAYIVFO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 879085-55-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
49701104, 56182549, 99431642, 99436972, 103596069, 104103799, 124756985, 124950698, 125163790, 126582948, 126723724, 131408297, 131480672, 134221782, 134964405, 135261181, 135264774, 135626713, 135693359, 135727390, 136367283, 136367935, 136920328, 137209785, 137275857, 139063406, 143499146, 144074933, 144116004, 152105953, 152237711, 152258215, 152344224, 160645549, 160647051, 160828460, 162011920, 162037423, 162201437, 163093562, 163390565, 164041956, 164193932, 164766132, 167250332, 170498924, 172919842, 174531169, 175265446, 175427109
|
|||
| ChEBI ID |
CHEBI:66903
|
|||
| ADReCS Drug ID | BADD_D02365 | |||
| SuperDrug ATC ID |
L01XX43
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Smoothened homolog (SMO) | Target Info | Modulator | [2] |
| KEGG Pathway | Hedgehog signaling pathway | |||
| Pathways in cancer | ||||
| Proteoglycans in cancer | ||||
| Basal cell carcinoma | ||||
| Panther Pathway | Hedgehog signaling pathway | |||
| Pathway Interaction Database | Signaling events mediated by the Hedgehog family | |||
| Hedgehog signaling events mediated by Gli proteins | ||||
| Reactome | Class B/2 (Secretin family receptors) | |||
| Hedgehog 'off' state | ||||
| Activation of SMO | ||||
| WikiPathways | Hedgehog Signaling Pathway | |||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| GPCR ligand binding | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975). | |||
| REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 3 | A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.